Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2021 update
• Spotlight

About Prescrire

• Who are we?
• How we work
• AMP: non-profit
• Financing
• "Non merci"
• Where to find us
• About Prescrire International
• Testimonials
• Prescrire events
• A global network

Offers

• Subscribe now
• Solidarity Subscription Rate
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

Prescrire's other websites

In Prescrire's Spotlight

Dapagliflozin (Forxiga°) and chronic heart failure FEATURED REVIEW An alternative to the sacubitril + valsartan combination, with the serious adverse effects common to all gliflozins. Full review (3 pages) available for download by subscribers. 1 December 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ In the December issue of Prescrire International - Teriparatide (Forsteo° and other brands) in pen injectors or cartridges: multidose formulations which must not be drawn into a syringe FREE DOWNLOAD Drawing the contents of a cartridge or prefilled pen into a syringe carries a risk of dosing errors. Full text available for free download. 1 December 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Full value  Editorial  Packaging is a key determinant of a medicinal product's quality. It is high time that pharmaceutical companies and drug regulatory agencies appreciated the full value of high-quality drug packaging. 1 December 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ The newly redesigned Prescrire International, from January 2022!  COMING SOON  From January 2022, the new, redesigned Prescrire International casts a critical eye on new drugs authorised in Europe. Don't miss out! 1 December 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Hypoglycaemia with loss of consciousness in insulin-treated patients: a treatment that is easier to administer When a patient with insulin-treated diabetes has lost consciousness due to hypoglycaemia, glucagon is the drug of choice. It is now available as a nasal spray (Baqsimi°), making it easier for the patient’s family or friends to manage severe hypoglycaemia. 1 December 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Haemorrhaging after childbirth: medicines are sometimes responsible Towards the end of pregnancy, the medicines the woman is taking, including serotonergic antidepressants (SSRIs and SNRIs), should be reviewed and sometimes adjusted, because some drugs can cause or worsen potentially fatal haemorrhages. 1 December 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ France's Mediator° trial reveals a cosy relationship between representatives of the French drug regulatory agency and an influential company The trial revealed how representatives of the agency, external experts charged with drug evaluation, and the company were constantly trying to come to a consensus, leading to a delay in the decision to withdraw Mediator° from the market. > Read more in our special section "Mediator° - the criminal trial" 1 December 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON Crizanlizumab to prevent vaso-occlusive crises in sickle-cell disease • Fenfluramine and Dravet syndrome • Clopidogrel + a proton pump inhibitor: increased mortality • DNDi: a collaborative research and development model focused on patients' needs... > Subscribe now 1 December 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Covid-19 : Follow Prescrire's independent, evidence-based analysis of the pandemic  COVID-19  Prescrire's editors are publishing an ongoing series of articles featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help healthcare professionals gain a clear and balanced view. 1 December 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ "Top Texts of 2021", from the editors of Prescrire International  NEW! FREE SPECIAL EDITION  Check out this brand new sampling of texts from Prescrire International, a wholly independent monthly drug bulletin, written by and for healthcare professionals. Inside, top articles from our "New Products", "Adverse Effects" and "Reviews" sections, plus our annual update of drugs to avoid. > Click here for your free copy 1 August 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on Facebook and Twitter Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on Facebook or > Follow us on Twitter 1 September 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International Subscribe now Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries). 1 September 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 September 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drugs to avoid, in the name of better patient care   DRUGS TO AVOID - 2021 UPDATE  Independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to prevent disproportionate harm to patients. > Read more

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page